

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b>  A61K 37/02	<b>A1</b>	<b>(11) International Publication Number:</b> WO 92/00751 <b>(43) International Publication Date:</b> 23 January 1992 (23.01.92)
<b>(21) International Application Number:</b> PCT/DK91/00193 <b>(22) International Filing Date:</b> 5 July 1991 (05.07.91)  <b>(30) Priority data:</b> 1628/90                      6 July 1990 (06.07.90)                      DK  <b>(71) Applicant (for all designated States except US):</b> NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> NIELSEN, Lars, Soegaard [DK/DK]; Teglvænget 14, DK-2990 Nivå (DK). MØLLER, Niels, Peter, Hundahl [DK/DE]; Heiterwanger Str. 32, 5, D-8000 München 70 (DE).		<b>(74) Common Representative:</b> NOVO NORDISK A/S; Patent Department, Novo Allé, DK-2880 Bagsværd (DK).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> A PHARMACEUTICAL COMPOSITION COMPRISING A CELL ADHESION MOLECULE  <b>(57) Abstract</b>  A pharmaceutical composition for the prophylaxis or treatment of diseases involving the binding of eosinophils to cells expressing surface vascular cell adhesion molecules comprises a vascular cell adhesion molecule (VCAM) or an anti-VCAM antibody and a pharmaceutically acceptable excipient or carrier. VCAM or anti-VCAM antibodies may also be used to screen for antagonists of VCAM binding to eosinophils.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

A PHARMACEUTICAL COMPOSITION COMPRISING A CELL ADHESION MOLECULE

FIELD OF THE INVENTION

5

The present invention relates to a pharmaceutical composition comprising a cell adhesion molecule or an antibody capable of binding the molecule, a method of screening for antagonists to the molecule, as well as a method of treatment using said  
10 antibody or molecule.

BACKGROUND OF THE INVENTION

It has previously been established that mammalian cells in  
15 general express different types of adhesion molecules on their surface mediating cell-to-matrix and cell-to-cell adhesion. Certain adhesion molecules serve specialized functions, one example being adhesion molecules which are expressed on the surface of endothelial cells as a result of cytokine induction,  
20 though other forms of induction may also exist. These adhesion molecules interact with structures on the surface of leukocytes so as to mediate the accumulation of white blood cells at sites of inflammation (e.g. caused by infection, injury, autoimmune reactions, allergies or vascular diseases).

25

The currently known inducible endothelial cell adhesion molecules are composed of an extracellular region which is capable of binding leukocytes, a transmembrane region which is responsible for anchoring the molecule in the cell membrane and  
30 which consists of approximately 22-23 amino acids, and a relatively short cytoplasmic region.

Until now, a variety of cell adhesion molecules has been identified. Thus, the intercellular adhesion molecule 1 (ICAM-  
35 1) has been cloned and characterized as described in, e.g. D. Simmons et al., Nature 331, 1988, pp. 624-627, EP 289 949, and D.E. Staunton et al., Cell 52, 1988, pp. 925-933, and the

endothelial leukocyte adhesion molecule (ELAM-1) has been identified and cloned as described in, e.g. M.P. Bevilacqua et al., Science 243, 1989, pp. 1160-1165. More recently, a vascular cell adhesion molecule (VCAM-1) has been identified  
5 and cloned (L. Osborn et al., Cell 59, 1989, pp. 1203-1211) and its properties described in M.J. Elices et al., Cell 60, 1990, pp. 577-584. This molecule was shown to bind certain lymphocytes and lymphocyte cell lines, but not granulocytes.

## 10 SUMMARY OF THE INVENTION

Contrary to what has previously been reported, it has surprisingly been found that the vascular cell adhesion molecule (VCAM) is capable of binding eosinophils. In normal  
15 immune response processes, this type of polymorphonuclear granulocyte is triggered to degranulate, i.e. to release its intracellular granules to the outside of the cell. Although this mechanism serves the purpose of combating pathogenic agents which cannot be phagocytosed, recent evidence shows that  
20 eosinophils also participate actively in a number of inflammatory diseases such as asthma, ulcerative colitis, rheumatoid arthritis and psoriasis (cf. P. Venge, Agents and Actions 29, 1990, pp. 122-126). Contrary to neutrophil granulocytes, the intracellular secretory granules of  
25 eosinophils contain strongly alkaline, cytotoxic substances which are assumed to be responsible for the tissue damage associated with these diseases.

A prerequisite for the accumulation of eosinophils at sites of  
30 inflammation is the binding of eosinophils to adhesion molecules, i.e. VCAM, present on endothelial cells. In view of this, it would be of considerable interest for the prophylaxis or treatment of chronic inflammatory conditions to prevent eosinophil binding to VCAMs.

35

Accordingly, the present invention relates to a pharmaceutical composition for the prophylaxis or treatment of diseases or

conditions involving the binding of eosinophils to cells expressing surface vascular cell adhesion molecules, the composition comprising a vascular cell adhesion molecule (VCAM) and a pharmaceutically acceptable carrier or excipient.

5

In another aspect, the present invention relates to a pharmaceutical composition for the prophylaxis or treatment of diseases or conditions involving the binding of eosinophils to cells expressing surface VCAMs, the composition comprising an antibody which is capable of binding a VCAM and a pharmaceutically acceptable carrier or excipient.

Diseases or conditions which may be treated by administration of the composition of the invention primarily include allergic diseases or conditions (e.g. asthma, inflammatory bowel disease or dermatitis) and autoimmune diseases (e.g. rheumatoid-arthritis or diabetes).

In the pharmaceutical composition of the invention, the VCAM or the antibody may be formulated by any of the established methods of formulating pharmaceutical compositions, e.g. as described in Remington's Pharmaceutical Sciences, 1985. The composition may typically be in a form suited for systemic or topical injection or infusion and may, as such, be formulated with a suitable carrier for injection or infusion, such as sterile water or an isotonic saline or glucose solution. The VCAM or antibody may also be formulated with a carrier such as a liposome (this being particularly advantageous for the membrane-bound form of the VCAM variant) or a polypeptide, e.g. albumin or globulin. It is at present assumed that the mode of action of the VCAM on administration is to bind to ligands on the surface of eosinophils, thereby inhibiting eosinophil binding to cells, such as vascular endothelial cells, expressing VCAMs and consequently ultimately preventing the eosinophils from penetrating into extravascular tissue. The antibody, on the other hand, is likely to act by binding to VCAMs expressed on the surface of cells, e.g. vascular

endothelial cells, whereby eosinophil binding to these cells is inhibited.

In a further aspect, the present invention relates to a method  
5 of screening for antagonists of VCAM binding to eosinophils, the method comprising incubating a VCAM or a cell capable of expressing a VCAM with a substance suspected to be an antagonist of VCAM binding and subsequently with eosinophils or a ligand derived from eosinophils and capable of binding  
10 VCAMs, and detecting any binding of the eosinophils or ligand to the VCAM, decreased binding indicating that said substance is an antagonist of VCAM binding.

In an alternative method of screening for antagonists of VCAM  
15 binding to eosinophils, eosinophils or a ligand derived from eosinophils and capable of binding VCAMs may be incubated with a substance suspected to be an antagonist of VCAM binding and subsequently with a VCAM or a cell capable of expressing VCAMs, and any binding of the eosinophils or ligand to the VCAM is  
20 detected, decreased binding indicating that said substance is an antagonist of VCAM binding.

#### DETAILED DESCRIPTION OF THE INVENTION

25 For pharmaceutical purposes, the VCAM is preferably in soluble form. This may be produced by truncating or substantially deleting DNA sequences of the molecule encoding the transmembrane and cytoplasmic regions of the VCAM. Alternatively, a soluble VCAM may be prepared by introducing  
30 a termination codon in the DNA sequence encoding the VCAM at a site upstream of the DNA sequences coding for the transmembrane and cytoplasmic regions. This facilitates the production of the VCAM since it will be secreted from cells containing the truncated DNA sequence substantially only  
35 encoding the extracellular region of the VCAM and may readily be isolated and purified from the culture medium of said cells rather than by the more cumbersome process of cell extraction.

Furthermore, a higher purity of the resulting VCAM is more easily achieved when it is in soluble form which facilitates the formulation of pharmaceutical compositions including the molecule. Apart from this, the soluble VCAM variant may  
5 suitably be used to screen for VCAM antagonists by procedures involving standard assays (e.g. bound to a chromatographic column or other solid support, as described in further detail below).

10 It has recently been found (cf. WO 90/13300) that VCAM exists in two forms, one comprising six immunoglobulin (Ig)-like domains (as described by L. Osborn et al., op. cit.), and a variant form comprising seven Ig-like domains. The present inventors currently believe the variant form to be the one most  
15 commonly expressed by vascular cells, and therefore most important for the present purpose. In a preferred embodiment, the pharmaceutical composition of the invention therefore includes the VCAM variant comprising seven Ig-like domains, or a derivative thereof.

20

The term "derivative" is used to indicate a polypeptide which is derived from the native VCAM variant by suitably modifying the DNA sequence coding for the variant, resulting in the addition of one or more amino acids at either or both the C-  
25 and N-terminal ends of the native amino acid sequence, substitution of one or more amino acids at one or more sites in the native amino acid sequence, deletion of one or more amino acids at either or both ends of the native sequence or at one or more sites within the native sequence, or insertion  
30 of one or more amino acids in the native sequence. It is understood that such derivatives should retain characterizing portion(s) of the native VCAM variant, in particular the additional Ig-like domain or a portion thereof.

35 The VCAM variant was initially cloned from endothelial cells and identified by sequencing. Like the previously described VCAM-1, the variant molecule has been found to exhibit amino

acid sequence and structural similarity to proteins of the Ig gene superfamily which are characterized by the presence of one or more Ig-like domains, each consisting of a disulfide-bridged loop which has a number of antiparallel  $\beta$ -pleated strands arranged in two sheets. Although molecules belonging to the Ig gene superfamily have a variety of functions, all cell membrane-bound forms are believed to play an important part in mediating cell surface recognition (for a more detailed description of the structure and function of Ig superfamily molecules, see A.F. Williams and A.N. Barclay, Ann. Rev. Immunol. 6, 1988, pp. 381-405, and T. Hunkapiller and L. Hood, Advances in Immunology 44, 1989, pp. 1-63). By comparing the amino acid sequences of VCAM-1 and the VCAM variant, it has been established that the additional Ig-like domain in the variant molecule occurs as the fourth such domain in the sequence, and that domains 1 and 4 as well as domains 2 and 5, and domains 3 and 6 exhibit a high degree of similarity in their respective amino acid sequences.

A preferred VCAM variant for the present purpose is one which includes amino acid sequence shown in Fig. 1 A-E or Fig. 3 A-D appended hereto, or a derivative thereof (as defined above).

It is currently assumed that each Ig-like domain may have a specific function in the VCAM variant molecule and that VCAM variants with different properties may be produced by interchanging and/or deleting one or more of the Ig-like domains. It is therefore contemplated that, in other VCAM variants useful for the present purpose, the amino acid sequence substantially corresponding to the additional Ig-like domain may equally be located in place of any one of the Ig-like domains 1, 2, 3, 5, 6 or 7 of the native sequence. Likewise, the order of the Ig-like domains 1-7 may be changed. Furthermore, one or more of the Ig-like domains 1, 2, 3, 5, 6 and 7 or parts thereof may be deleted, the deletion optionally being the result of alternative splicing. Thus, deletions may occur at either the N- or C-terminal end of the molecule or



within the sequence. Thus, it may be envisaged that the VCAM variant may be one with N-terminal deletions in the Ig-like domain 1 or a part thereof, Ig-like domains 1-2 or a part thereof, or Ig-like domains 1-3 or a part thereof.

5

The VCAM variant may most conveniently be prepared by introducing a DNA construct which comprises a DNA sequence encoding the VCAM variant into a suitable recombinant expression vector, and transforming a suitable cell with said recombinant expression vector. The transformed cell may then be cultured in a suitable nutrient medium under conditions which are conducive to the expression of the VCAM variant, and the VCAM variant may be recovered from the culture.

15 The DNA construct is preferably one which comprises the DNA sequence shown in the appended Fig. 1 A-E or Fig. 3 A-D or a suitable modification thereof. Examples of suitable modifications of the DNA sequence are nucleotide substitutions which do not give rise to another amino acid sequence of the VCAM variant, but which correspond to the codon usage of the host organism into which the DNA construct is introduced or nucleotide substitutions which do give rise to a different amino acid sequence and therefore, possibly, a different protein structure without, however, impairing the properties of the native variant. Other examples of possible modifications are insertion of one or more nucleotides into the sequence, addition of one or more nucleotides at either end of the sequence, or deletion of one or more nucleotides at either end or within the sequence.

30

Another preferred DNA construct is one which encodes a soluble form of the VCAM variant. This may for instance be obtained by truncating or substantially deleting the DNA sequences of the DNA construct coding for the transmembrane and cytoplasmic regions of the VCAM variant. Alternatively, the DNA construct may comprise a termination codon at a site upstream of the DNA sequences coding for the transmembrane and cytoplasmic regions.

35

The DNA construct encoding the VCAM variant may be prepared synthetically by established standard methods, e.g. the phosphoramidite method described by S.L. Beaucage and M.H. Caruthers, Tetrahedron Letters 22, 1981, pp. 1859-1869, or the  
5 method described by Matthes et al., EMBO Journal 3, 1984, pp. 801-805. According to the phosphoramidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.

10

The DNA construct may also be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the VCAM variant of the invention by hybridization using synthetic  
15 oligonucleotide probes in accordance with standard techniques (cf. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989). In this case, a genomic or cDNA sequence encoding the VCAM variant may be modified at a site corresponding to the site(s) at which it is desired to  
20 introduce amino acid substitutions, e.g. by site-directed mutagenesis using synthetic oligonucleotides encoding the desired amino acid sequence for homologous recombination in accordance with well-known procedures.

25 Finally, the DNA construct may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA origin prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various parts of the entire DNA construct, in accordance with  
30 standard techniques. The DNA construct may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202 or R.K. Saiki et al., Science 239, 1988, pp. 487-491.

35 The recombinant expression vector into which the DNA construct is inserted may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of

vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

10 In the vector, the DNA sequence encoding the VCAM variant should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA encoding the VCAM variant in mammalian cells are the SV 40 promoter (Subramani et al., Mol. Cell Biol. 1, 1981, pp. 854-864), the MT-1 (metallothionein gene) promoter (Palmiter et al., Science 222, 1983, pp. 809-814) or the adenovirus 2 major late promoter. Suitable promoters for use in yeast host cells include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. 255, 1980, pp. 12073-12080; Alber and Kawasaki, J. Mol. Appl. Gen. 1, 1982, pp. 419-434) or alcohol dehydrogenase genes (Young et al., in Genetic Engineering of Microorganisms for Chemicals (Hollaender et al, eds.), Plenum Press, New York, 1982), or the TPI1 (US 4, 599, 311) or ADH2-4c (Russell et al., Nature 304, 1983, pp. 652-654) promoters. Suitable promoters for use in filamentous fungus host cells are, for instance, the ADH3 promoter (McKnight et al., The EMBO J. 4, 1985, pp. 2093-2099) or the tpiA promoter.

The DNA sequence encoding the VCAM variant may also be operably connected to a suitable terminator, such as the human growth hormone terminator (Palmiter et al., op. cit.) or (for fungal hosts) the TPI1 (Alber and Kawasaki, op. cit.) or ADH3

(McKnight et al., op. cit.) promoters. The vector may further comprise elements such as polyadenylation signals (e.g. from SV 40 or the adenovirus 5 Elb region), transcriptional enhancer sequences (e.g. the SV 40 enhancer) and translational enhancer sequences (e.g. the ones encoding adenovirus VA RNAs).

The recombinant expression vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. An examples of such a sequence (when the host cell is a mammalian cell) is the SV 40 origin of replication. The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or one which confers resistance to a drug, e.g. neomycin, hygromycin or methotrexate.

The procedures used to ligate the DNA sequences coding for the VCAM variant of the invention, the promoter and the terminator, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., op.cit.).

The host cell into which the expression vector is introduced may be any cell which is capable of producing the VCAM variant and is preferably a eukaryotic cell, in particular a mammalian cell. Examples of suitable mammalian cell lines are the COS (ATCC CRL 1650), BHK (ATCC CRL 1632, ATCC CCL 10) or CHO (ATCC CCL 61) cell lines. Methods of transfecting mammalian cells and expressing DNA sequences introduced in the cells are described in e.g. Kaufman and Sharp, J. Mol. Biol. **159**, 1982, pp. 601-621; Southern and Berg, J. Mol. Appl. Genet. **1**, 1982, pp. 327-341; Loyter et al., Proc. Natl. Acad. Sci. USA **79**, 1982, pp. 422-426; Wigler et al., Cell **14**, 1978, p. 725; Corsaro and Pearson, Somatic Cell Genetics **7**, 1981, p. 603, Graham and van der Eb, Virology **52**, 1973, p. 456; and Neumann et al., EMBO J. **1**, 1982, pp. 841-845.

Alternatively, fungal cells (including yeast cells) may be used as host cells. Examples of suitable yeast cells include cells of Saccharomyces spp. or Schizosaccharomyces spp., in particular strains of Saccharomyces cerevisiae. Examples of  
5 other fungal cells are cells of filamentous fungi, e.g. Aspergillus spp. or Neurospora spp., in particular strains of Aspergillus oryzae or Aspergillus niger. The use of Aspergillus spp. for the expression of proteins is described in, e.g., EP 272 277.

10

The medium used to culture the cells may be any conventional medium suitable for growing mammalian cells, such as a serum-containing or serum-free medium containing appropriate supplements. Suitable media are available from commercial  
15 suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection).

If the VCAM variant produced by the cells is one which is deleted of or truncated in the transmembrane and cytoplasmic  
20 regions of the native variant, it will be secreted to the growth medium and may be recovered from the medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by  
25 means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, affinity chromatography, or the like.

If the VCAM variant has retained the transmembrane and  
30 (possibly) the cytoplasmic region of the native variant, it will be anchored in the membrane of the host cell and may either be purified therefrom by conventional purification procedures, or the cells carrying the VCAM variant may be used as such in the screening assay. As noted above, however, it may  
35 be preferred for some applications that the VCAM variant is in soluble form.

The anti-VCAM antibody is preferably one which is raised against an epitope at least partially included in the following amino acid sequence

5 Glu Lys Pro Phe Thr Val Glu Ile Ser Pro Gly Pro Arg Ile Ala Ala  
Gln Ile Gly Asp Ser Val Met Leu Thr Cys Ser Val Met Gly Cys Glu  
Ser Pro Ser Phe Ser Trp Arg Thr Gln Ile Asp Ser Pro Leu Asn Gly  
Lys Val Arg Ser Glu Gly Thr Asn Ser Thr Leu Thr Leu Ser Pro Val  
Ser Phe Glu Asn Glu His Ser Tyr Leu Cys Thr Val Thr Cys Gly His  
10 Lys Lys Leu Glu Lys Gly Ile Gln Val Glu Leu Tyr Ser

This sequence substantially corresponds to the additional Ig-like domain of the native VCAM variant as described above, thus ensuring specificity of the antibody against the variant. For  
15 this reason, it is preferred that the antibody is a monoclonal antibody or a fragment thereof, such as a F(ab')<sub>2</sub> or Fab' fragment, prepared as described in e.g. A. Johnstone and R. Thorpe, Immunochemistry in Practice, 2nd Ed., Blackwell Scientific Publications, 1987, pp. 35-43.

20

In the screening method of the invention, the VCAM, in particular the VCAM variant, or the anti-VCAM antibody may be immobilized on a solid support. Alternatively, the VCAM or anti-VCAM antibody may be provided with a suitable label. The  
25 VCAM may either be used in soluble form immobilized on a solid support, or it may be used in membrane-bound form, i.e. bound to whole cells or as a component of membrane preparations.

The solid support employed in the screening method of the  
30 invention preferably comprises a polymer. The support may in itself be composed of the polymer or may be composed of a matrix coated with the polymer. The matrix may be of any suitable material such as glass, paper or plastic. The polymer may be selected from the group consisting of a plastic (e.g.  
35 latex, a polystyrene, polyvinylchloride, polyurethane, polyacrylamide, polyvinylalcohol, nylon, polyvinylacetate, and any suitable copolymer thereof), cellulose (e.g. various types

of paper, such as nitrocellulose paper and the like), a silicon polymer (e.g. siloxane), a polysaccharide (e.g. agarose or dextran), an ion exchange resin (e.g. conventional anion or cation exchange resins), a polypeptide such as polylysine, or  
5 a ceramic material such as glass (e.g. controlled pore glass).

The physical shape of the solid support is not critical, although some shapes may be more convenient than others for the present purpose. Thus, the solid support may be in the shape  
10 of a plate, e.g. a thin layer or microtiter plate, or a film, strip, membrane (e.g. a nylon membrane or a cellulose filter) or solid particles (e.g. latex beads or dextran or agarose beads).

15 The label substance with which the VCAM or anti-VCAM antibody may be labelled is preferably selected from the group consisting of enzymes, coloured or fluorescent substances, radioactive isotopes and complexing agents.

20 Examples of enzymes useful as label substances are peroxidases (such as horseradish peroxidase), phosphatases (such as acid or alkaline phosphatase),  $\beta$ -galactosidase, urease, glucose oxidase, carbonic anhydrase, acetylcholinesterase, glucoamylase, lysozyme, malate dehydrogenase, glucose-6-  
25 phosphate dehydrogenase,  $\beta$ -glucosidase, proteases, pyruvate decarboxylase, esterases, luciferase, etc.

Enzymes are not in themselves detectable but must be combined with a substrate to catalyse a reaction the end product of  
30 which is detectable. Examples of substrates which may be employed in the method according to the invention include hydrogen peroxide/tetramethylbenzidine or chloronaphthole or o-phenylenediamine or 3-(p-hydroxyphenyl) propionic acid or luminol, indoxyl phosphate, p-nitrophenylphosphate, nitrophenyl  
35 galactose, 4-methyl umbelliferyl-D-galactopyranoside, or luciferin.

Alternatively, the label substance may comprise coloured or fluorescent substances, including gold particles, coloured or fluorescent latex particles, dye particles, fluorescein, phycoerythrin or phycocyanin.

5

Radioactive isotopes which may be used for the present purpose may be selected from I-125, I-131, In-111, H-3, P-32, C-14 or S-35. The radioactivity emitted by these isotopes may be measured in a gamma-counter or a scintillation camera in a  
10 manner known per se.

Complexing agents which may be employed for the present purpose may be selected from biotin (which complexes with avidin or streptavidin), avidin (which complexes with biotin), Protein  
15 A (which complexes with immunoglobulins) and lectins (complexing with carbohydrate receptors). As the complex is not directly detectable, it is necessary to label the substance with which the complexing agent forms a complex. The labelling may be carried out with any one of the label substances  
20 mentioned above for the labelling of the enzyme.

The eosinophil-derived ligand capable of binding VCAM, which ligand may be used in the screening method of the invention, may be used in isolated form and may, as such, be provided with  
25 a label or may be immobilized on a solid support, respectively, as described above. However, the ligand may also be used in membrane-bound form, i.e. bound to whole cells or as a component of membrane preparations. If the ligand is bound to whole cells (expressed on their surface), binding of the ligand  
30 to VCAM may be measured by counting the cells visually, or by measuring naturally occurring intracellular enzyme activity, e.g. peroxidase activity, or by measuring enzyme activity introduced into the cells by recombinant DNA techniques. An example of a useful ligands is very late antigen-4 (VLA-4) (a  
35 molecule which acts as a specific ligand for VCAMs on the surface of eosinophils (and other leukocytes)).



The present invention also relates to a method of preventing or treating diseases or conditions involving the binding of eosinophils to cells expressing VCAMs, the method comprising administering, to a patient in need thereof, an effective  
5 dosage of a VCAM or anti-VCAM antibody, as described above.

The invention further relates to the use of VCAM, an anti-VCAM antibody or a VCAM antagonist identified by the method of the invention for the preparation of a medicament for the  
10 prophylaxis or treatment of diseases or conditions involving the binding of eosinophils to cells expressing VCAMs. As indicated above, it is preferred that the VCAM used for this purpose is in soluble form.

15 It is furthermore contemplated to locate the ligand-binding site on the VCAM variant of the invention, for instance by preparing deletion derivatives of the native VCAM variant (as described above) and incubating these with ligands known to bind the full-length VCAM variant (e.g. an anti-VCAM antibody,  
20 VLA-4 or cells expressing VCAM ligands on their surface) and detecting any binding of the ligand to the VCAM deletion derivative. Once the ligand-binding site has been located, this may be used to acquire further information about the three-dimensional structure of the ligand-binding site. Such three-  
25 dimensional structures may, for instance, be established by means of protein engineering, computer modelling and/or crystallographic techniques. Based on the three-dimensional structure of the ligand-binding site, it may be possible to design substances which are antagonists of intercellular  
30 binding by binding to VCAM and which have a three-dimensional structure substantially complementary to that of the ligand-binding site.

#### BRIEF DESCRIPTION OF THE DRAWINGS

35

The present invention is further illustrated in the following examples with reference to the appended drawings in which

Fig. 1 A-E shows the cDNA sequence of the native full-length VCAM variant of the invention and the deduced amino acid sequence,

5 Fig. 2 shows a comparison between the 93 amino acid additional Ig-like domain of the VCAM variant of the invention (top) and the first part of the published VCAM sequence (bottom), and

Fig. 3 A-D shows the cDNA sequence of a soluble VCAM variant  
10 of the invention and the deduced amino acid sequence.

The present invention is further illustrated in the following examples which are not intended to be in any way limiting to the scope of the invention as claimed.

15

#### Example 1

#### **Construction of a cDNA encoding a VCAM variant with 7 Ig-like domains**

20

Human umbilical vein endothelial cell cultures were established essentially by the method described by Jaffe et al., 1973. J. Clin. Invest. 52: 2745-2756. Cultures in low passage numbers were treated with phorbol myristate acetate (PMA) at a concentration of 50 nM for 3-7 hours, after which the cells were  
25 harvested and frozen. Total RNA from the cells were prepared by a single-step guanidinium thiocyanate-phenol-chloroform extraction procedure (P. Chomczynski and N. Sacchi. 1987. Anal. Biochem. 162: 156-159). First strand cDNA was synthesized using  
30 7 µg of total RNA per experiment. For some experiments first strand synthesis was primed by a 17-mer oligo dT primer, while for other experiments a specific VCAM 3' oligonucleotide primer 5'-ATCAAGACTAGTCTACACTTTTGATTTCTGTGCTTC-3' was used. Reagents used for synthesis of first strand cDNA by reverse trans-  
35 cription was from a commercial cDNA synthesis kit (Riboclone cDNA synthesis system, Promega Corporation, Madison, WI, USA) and reaction conditions were as recommended by the manufac-

turer.

VCAM cDNA fragments were prepared from first strand cDNA by polymerase chain reaction using specific oligonucleotide primers (R.K. Saiki et al. 1988. Science 239: 487-491). PCR was performed using the Gene Amp kit (Perkin Elmer Cetus, Norwalk, CT, USA).

In each PCR, approximately 1-3 µg of reverse transcribed mRNA was used as template. The following specific primers were used for PCR:

1. 5'-CAG CAA GGT ACC ATG CCT GGG AAG ATG GTC GTG ATC C-3'
2. 5'-AAG GTG CTG CAG ATT CCC ATT ATC TAA TTT CTT ACT-3'
- 15 3. 5'-GAA ATT AGA TAA TGG GAA TCT GCA GCA CCT TTC TGG A-3'
4. 5'-ATC AAG ACT AGT CTA CAC TTT TGA TTT CTG TGC TTC-3'

Mismatches were introduced in the primers compared with the published VCAM cDNA sequence (L. Osborn et al. 1989. Cell 59: 1203-1211) thus creating endonuclease restriction sites to facilitate subcloning and assembly into appropriate cloning vectors of amplified cDNA fragments. Two of these sites (primer 1: a KpnI site, primer 4: a SpeI site) were located outside the protein coding region, while the other two (primers 2 and 3: PstI sites) did not affect the amino acid sequence of the protein encoded by the constructed cDNA. Each PCR reaction cycle comprised denaturation of the template at 94°C for 1 minute, annealing of the primers to the templates for 2 minutes at 50°C, followed by extension of the primers for 3 minutes at 72°C. This cycle was repeated 25 times, resulting in specific VCAM cDNA fragments.

When PCR was performed using primers 1 and 2, a fragment of the expected size (~800 bp) resulted. Surprisingly, however, when PCR was performed with primers 3 and 4, a fragment of approximate size 1400 bp (expected: 1162) resulted. The experiment was repeated several times with the same result. PCR performed with

primers 1 and 4 resulted in a fragment of approximately 2200 bp compared to the expected size of 1968 bp.

The isolated cDNA fragments were digested with the endonucleases (New England Biolabs, MA, USA) KpnI and PstI (primer combination: 1 and 2) or PstI and SpeI (primer combination 3 and 4), and the two fragments were subcloned separately into the pBluescript II KS+ vector (Stratagene, CA, USA) by the method described by Sambrook et al. (Molecular cloning. A laboratory manual (J. Sambrook, E.F. Fritsch and T. Manuatis, eds.), Cold Spring Harbor Laboratory Press, 1989). Cells of E. coli strain XL-1 Blue (Stratagene, CA, USA) were made competent according to the method of Hanahan (1983. J. Mol. Biol. 166: 557-580) and used for transformation with the vectors indicated above. The VCAM cDNA was assembled from two subcloned cDNA fragments (KpnI-PstI, PstI-SpeI) according to the method described by Sambrook et al. (Molecular Cloning. A laboratory Manual (J. Sambrook, E.F. Fritsch and T. Maniatis, eds.), Cold Spring Harbor Laboratory Press, 1989) in the mammalian cell expression vector Zem219b (described in DK Patent Application No. 3023/88) in which the oligonucleotide 5'-GATCCGGTACCT-3' had been inserted between the BamHI and the first XbaI site resulting in the introduction of a KpnI cloning site. This VCAM expression vector was termed pVCAM-exp.

The cDNA fragments were sequenced by the enzymatic chain termination method described by Sanger et al., Proc. Natl. Acad. Sci. USA. 1977. 74: 5463-5467, using T7 DNA polymerase (Sequenase Kit, USB, Cleveland, Ohio, USA).

The DNA sequence of VCAM cDNA isolated as described is shown in Fig. 1 A-E. The sequence was identical to the published sequence (L. Osborn et al., 1989. Cell 59: 1203-1211) except for three base differences (A -> G in position 269, T -> A in position 792 due to the introduction of a PstI site, and A -> G in position 1790 resulting in Gln -> Arg) and the unexpected finding of additionally 276 bases after base 928 between C and

G in an alanine codon resulting in the loss of an alanine residue and the addition of 93 amino acid residues to the published sequence. This localization of the additional amino acids corresponds exactly to the transition between  
5 immunoglobulin domain 3 and 4 of the amino acid sequence encoded by the published VCAM cDNA sequence.

Using the GAP function of the University of Wisconsin, Genetics Computer Group programme (J. Devereux et al., 1984. Nucleic  
10 Acids Res. 12: 387-395), the amino acid sequence encoded by the cDNA insertion was compared to all five immunoglobulin domains encoded by the published VCAM cDNA sequence. Fig. 2 shows that a very high degree of identity (72 %) was found to the first Ig domain of VCAM.

15

Taken together the sequence data presented definitively identifies a hitherto unknown molecular form of the VCAM molecule with an additional seventh Ig domain.

## 20 Example 2

### Construction of a cDNA encoding a soluble VCAM variant with 7 Ig-like domains

25 Using the cloned VCAM cDNA inserted in the mammalian cell expression vector Zem219b (see **Example 1**) as a template a cDNA encoding a soluble form of the VCAM molecule was constructed by polymerase chain reaction (PCR) using specific oligonucleotide primers (R.K. Saiki et al., 1988. Science 239:  
30 487-491). PCR was performed using the Gene Amp kit (Perkin Elmer Cetus, Norwalk, CT, USA) according to the manufacturer's instructions.

The PCR was performed using 50 ng of the pVCAM-exp plasmid as template. The following specific primers were used:

35

1. 5'-CAG CAA GGT ACC ATG CCT GGG AAG ATG GTC GTG ATC C-3'
2. 5'-CAC GAG ACT AGT CTA AGA AAA ATA GTC TTT GTT GTT TTC-3'

Mismatches were introduced in primer 2 compared with the published VCAM cDNA sequence (L. Osborn et al. 1989. Cell 59: 1203-1211) thus creating an endonuclease restriction site (SpeI) to permit subcloning into the Zem219b (described in DK Patent Application No. 3023/88) expression vector and further-  
5 more creating a translation stop codon resulting in deletion of the putative transmembrane and cytoplasmic domains of the encoded VCAM protein. Each PCR reaction cycle comprised denaturation of the template at 94°C for 1 minute, annealing  
10 of the primers to the templates for 2 minutes at 50°C, followed by extension of the primers for 3 minutes at 72°C. this cycle was repeated 10 times.

The isolated approximately 2.2 kb cDNA fragment was digested  
15 with the endonucleases (New England Biolabs, MA, USA) KpnI and SpeI and subcloned into the Zem219b mammalian cell expression vector by the method described by Sambrook et al. (Molecular cloning. A laboratory manual (J. Sambrook, E.F. Fritsch and T. Maniatis, eds.), Cold Spring Harbor Laboratory Press, 1989).  
20 The sequence of the subcloned cDNA was verified by the enzymatic chain termination sequencing method described by Sanger et al., Proc. Natl. Acad. Sci. USA. 1977. 74: 5463-5467, using T7 DNA polymerase (Sequenase Kit, USB, Cleveland, Ohio, USA) and found to be identical to the sequence described in Example  
25 1 except for the presence of the termination codon introduced into the sequence.

The DNA sequence of the cDNA encoding a putative soluble form of VCAM with 7 Ig domains isolated as described is shown in  
30 Fig. 3 A-D together with the deduced amino acid sequence.

### Example 3

**Adherence assay of HL-60 cells and COS-7 cells transfected with  
35 a cDNA encoding wild type VCAM with 7 Ig homology units**

### **Materials and methods**

**Cell lines:** COS-7 cells (ATCC CRL 1651) were cultured in DMEM containing 10% FCS, 100 U/ml of penicillin and 100 µg/ml of streptomycin.

- 5 HL-60 cells (ATCC CCL 240) were cultured in RPMI 1640 medium containing 10% FCS, 100 U/ml of penicillin and 100 µg/ml of streptomycin.

**DNA constructs:** The mammalian expression vector Zem 129b is  
10 described in DK Patent Application No. 3023/88.

The wild-type VCAM cDNA encoding seven Ig homology units were inserted into Zem 219b as described in Example 1 resulting in the expression plasmid pVCAM-exp.

15

**Transfections:** Transfection of COS cells in Petri dishes was performed with the plasmids Zem 219b and pVCAM-exp using the calcium phosphate technique (F.L. Graham and A.J. van der Eb. 1973. Virology 52: 456-467) with the modifications described  
20 in: "DNA Cloning, A Practical Approach" (Glover, D.M.), vol. I + II. 1985. IRL Press. Twenty µg of DNA was used per transfection. Sixteen hours post transfection the media were changed, and 32 hours later the transfected cells were used for adherence assay.

25

**Adherence assay:** Transfected COS-7 cells were washed once with RPMI 1640 containing 1% FCS (assay medium). HL-60 cells were washed once with assay medium, and  $6 \times 10^6$  cells in a total volume of 3 ml were applied to each COS-7 Petri dish. After 30  
30 min incubation at room temperature the cells were washed twice with assay medium, and the result evaluated.

**Results:** Visual evaluation after transfection and adherence assay showed a very low level of HL-60 binding to mock trans-  
35 fected (Zem 219b) COS cells, while the major part of HL-60 cells present adhered to COS cells transfected with pVCAM-exp.

These results demonstrate the ability of VCAM cDNA encoding 7 Ig homology units to encode a protein with adhesive properties towards a leukocyte cell line.

5 Example 4

**Adherence assay of baby hamster kidney cells expressing VCAM comprising 7 Ig-like domains and eosinophil and neutrophil granulocytes**

10

Baby hamster kidney cells (ATCC CCL 10) were transfected with the cloned VCAM cDNA inserted into the mammalian cell expression vector Zem219b (see Example 1) using a modification of the calcium phosphate coprecipitation technique (C. Chen and  
15 H. Okayama, Mol. Cell. Biol. 7, 1987, pp. 2745-2752). 0.25 x 10<sup>6</sup> cells were seeded in DMEM containing 10 % FCS, 100 U/ml of penicillin and 100 µg/ml of streptomycin in a plastic Petri dish. The following day transfection was performed with 20 µg of DNA. The next day the cells were seeded in Petri dishes each  
20 containing 2 % of the cells. After 24 hours selection of transfectants was started using the above mentioned medium with the addition of 1 µM methotrexate. Selected clones were transferred to tissue culture flasks using cloning rings and tested for VCAM expression using the procedure described in  
25 Example 3. Ten clones tested all showed VCAM-1 expression.

Granulocytes were prepared by dextran sedimentation followed by percoll gradient centrifugation. Briefly, 40 ml of heparinized blood was mixed with an equal amount of dextrane  
30 solution (2 g/100 ml Dextrane T-500 (Pharmacia), 0.9 g/100 ml NaCl). After incubation for 30 min. at room temperature, the supernatant was centrifuged for 5 min. at 250 g. The pellet was resuspended in PBS to a cell concentration of 8.3 x 10<sup>6</sup>/ml. A Percoll gradient was prepared containing 72, 68, 66, 63, 59 and  
35 54 % Percoll (100 % = Percoll 1.131 g/ml) with a total volume of 8 ml. 3 ml of cell suspension was placed on top of the gradient and centrifuged for 35 minutes at 600 g and room



temperature. After centrifugation the cell bands were aspirated, washed, and resuspended in PBS. Differential counts of the various preparations were performed by May-Grünwald staining. Granulocyte fractions containing 16.0% eosinophils, 82.8% neutrophils and 1.2% mononuclear cells were used in the following experiments.

The day before adherence experiments 25,000 untransfected or VCAM-1 transfected BHK cells were seeded in 24 well cell culture plates (NUNC, Denmark) in DMEM medium with methotrexate as described above. The following day granulocytes were prepared from a normal volunteer as described above and resuspended to a cell concentration of  $0.27 \times 10^6$  cells/ml in assay buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 1 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ ). Transfected and untransfected BHK cells were washed twice with assay buffer and incubated with 1 ml of the granulocyte cell suspension at 37°C for 30 minutes. The cells were washed twice with assay buffer, scraped off, lysed with 0.5 % N-cetyl-N,N,N-trimethylammoniumbromide (CTAB) and centrifuged. The supernatants were assayed by radioimmunoassay for the eosinophil specific protein eosinophil cationic protein (ECP) as described (P. Venge et al., Br. J. Haematol. 27, 1977, pp. 331-335). Similarly the supernatants were assayed by RIA for the neutrophil specific protein myeloperoxidase (MPO) (T. Oloffson et al., Scand. J. Haematol. 18, 1977, pp. 73-88).

The results of this experiment are shown in Table I. When transfected and non-transfected cells were lysed and assayed as described above, no ECP or MPO could be detected (results not shown).

As appears from Table I eosinophils adhere strongly to VCAM-1 expressing BHK cells, in contrast to neutrophils, which show no adhesion above background levels. Similar experiments were performed with granulocytes from 3 asthma patients with high eosinophil counts with essentially similar results.

5

10	Cell fraction	added $\times 10^{-6}$	added $\times 10^{-6}$	Eosinophils		Neutrophils	
				ECP ng	ECP %	MPO ng	MPO %
15	Granulocyte start fraction	0.043	0.222	100	435	1033	100
	Granulocytes adhering to VCAM-1 cells	0.043	0.222	173	39.7	89	8.6
20	Granulocytes adhering to control cells	0.043	0.222	45.3	10.4	57	5.5

25

## CLAIMS

1. A pharmaceutical composition for the prophylaxis or treatment of diseases or conditions involving the binding of eosinophils to cells expressing surface vascular cell adhesion molecules, the composition comprising a vascular cell adhesion molecule (VCAM) and a pharmaceutically acceptable carrier or excipient.
2. A composition according to claim 1, wherein the VCAM is in soluble form.
3. A composition according to claim 1 or 2, wherein the VCAM is a VCAM variant comprising seven immunoglobulin (Ig)-like domains, or a derivative thereof.
4. A composition according to claim 3, wherein the VCAM variant comprises the amino acid sequence shown in Figs. 1 A-E or 3 A-D appended hereto, or a derivative thereof.
5. A composition according to claim 3, wherein one or more of the Ig-like domains 1, 2, 3, 5, 6 and 7 of the VCAM variant are deleted.
6. A composition according to any of claims 1-5, wherein the VCAM is fused to another Ig superfamily molecule or a fragment thereof.
7. A composition according to any of claims 1-6 for the prophylaxis or treatment of allergic diseases or conditions, such as asthma, inflammatory bowel disease or dermatitis.
8. A composition according to any of claims 1-6 for the prophylaxis or treatment of autoimmune diseases, such as rheumatoid arthritis or diabetes.
9. A pharmaceutical composition for the prophylaxis or

treatment of diseases or conditions involving the binding of eosinophils to cells expressing surface vascular cell adhesion molecules, the composition comprising an antibody which is capable of binding a VCAM and a pharmaceutically acceptable  
5 excipient or carrier.

10. A composition according to claim 9, wherein the antibody is one which is capable of specifically binding a VCAM variant comprising seven Ig-like domains.

10

11. A composition according to claim 10 comprising an antibody which reacts specifically with an epitope at least partially included in the following amino acid sequence

15 Glu Lys Pro Phe Thr Val Glu Ile Ser Pro Gly Pro Arg Ile Ala Ala  
Gln Ile Gly Asp Ser Val Met Leu Thr Cys Ser Val Met Gly Cys Glu  
Ser Pro Ser Phe Ser Trp Arg Thr Gln Ile Asp Ser Pro Leu Asn Gly  
Lys Val Arg Ser Glu Gly Thr Asn Ser Thr Leu Thr Leu Ser Pro Val  
Ser Phe Glu Asn Glu His Ser Tyr Leu Cys Thr Val Thr Cys Gly His  
Lys Lys Leu Glu Lys Gly Ile Gln Val Glu Leu Tyr Ser

20

12. A composition according to any of claims 9-11, wherein the antibody is a monoclonal antibody or a fragment thereof.

13. A method of screening for antagonists of VCAM binding to  
25 eosinophils, the method comprising incubating a VCAM or a cell capable of expressing a VCAM with a substance suspected to be an antagonist of VCAM binding and subsequently with eosinophils or a ligand derived from eosinophils and capable of binding VCAMs, and detecting any binding of the eosinophils or ligand  
30 to the VCAM, decreased binding indicating that said substance is an antagonist of VCAM binding.

14. A method of screening for antagonists of VCAM binding to  
eosinophils, the method comprising incubating eosinophils or  
35 a ligand derived from eosinophils and capable of binding VCAMs with a substance suspected to be an antagonist of VCAM binding and subsequently with a VCAM or a cell capable of expressing

VCAMs, and detecting any binding of the eosinophils or ligand to the VCAM, decreased binding indicating that said substance is an antagonist of VCAM binding.

- 5 15. A method according to claim 13 or 14, wherein the ligand derived from eosinophils capable of binding the VCAM variant is very late antigen-4 (VLA-4).
- 10 16. A method according to claim 13 or 14, wherein the VCAM is a VCAM variant comprising seven Ig-like domains, or a derivative thereof.
- 15 17. A method according to claim 16, wherein the VCAM variant comprises the amino acid sequence shown in the appended Figs. 1 A-E or 3 A-D, or a derivative thereof.
- 20 18. A method of preventing or treating a disease or condition involving the binding of eosinophils to cells expressing surface VCAMs, the method comprising administering, to a patient in need thereof, an effective dosage of a pharmaceutical composition according to any of claims 1-8 or 9-12.
- 25 19. A method according to claim 18, wherein the disease or condition is an allergic disease or condition, such as asthma, inflammatory bowel disease or dermatitis, or an autoimmune disease, such as rheumatoid arthritis or diabetes.
- 30 20. Use of a VCAM for the preparation of a medicament for the prophylaxis or treatment of diseases or conditions involving the binding of eosinophils to cells expressing surface VCAMs.
- 35 21. Use according to claim 20, wherein the VCAM is a VCAM variant comprising seven Ig-like domains, or a derivative thereof.
22. Use according to claim 20 or 21, wherein the VCAM is in

soluble form.

23. Use according to claim 21 or 22, wherein the VCAM variant comprises the amino acid sequence shown in the appended Figs.  
5 1 A-E or 3 A-D, or a derivative thereof,.

24. Use according to any of claims 20-23, wherein the disease or condition is an allergic disease or condition, such as asthma, inflammatory bowel disease or dermatitis, or an  
10 autoimmune disease, such as rheumatoid arthritis or diabetes.

25. Use of an antibody capable of binding to a VCAM for the preparation of a medicament for the prophylaxis or treatment of diseases or conditions involving the binding of eosinophils  
15 to cells expressing surface VCAMs.

26. Use according to claim 25, wherein the antibody is capable of binding specifically to a VCAM variant comprising seven Ig-like domains, or a derivative thereof.

20 27. Use according to claim 25 or 26, wherein the disease or condition is an allergic disease or condition, such as asthma, inflammatory bowel disease or dermatitis, or an autoimmune disease, such as rheumatoid arthritis or diabetes.

25 28. Use of a VCAM antagonist isolated by the method of any of claims 13-17 for the preparation of a medicament for the prophylaxis or treatment of diseases or conditions involving the binding of eosinophils to cells expressing surface VCAMs.

30 29. Use of a VCAM derivative on which the ligand-binding site has been identified for establishing the three-dimensional structure of the ligand-binding site and designing a substance which is an antagonist of VCAM binding to cellular ligands,  
35 which substance has a three-dimensional structure which is substantially complementary to the three-dimensional structure of the ligand-binding site on the VCAM.

1/14

```

1  ATGCCTGGGAAGATGGTCGTGATCCTTGGAGCCTCAAATATACTTTGGATAAATGTTTGCA 60
   +-----+-----+-----+-----+-----+-----+
   TACGGACCCCTTCTACCAAGCACTAGGAACCTCGGAGTTTATATGAACCTATTACAAACGT
   MetProGlyLysMetValValIleLeuGlyAlaSerAsnIleLeuTrpIleMetPheAla -
61  GCTTCTCAAGCTTTTAAAAATCGAGACCAACCCAGAAATCTAGATATCTTGCTCAGATTGGT 120
   +-----+-----+-----+-----+-----+-----+
   CGAAGAGTTCGAAAATTTTAGCTCTGGTGGGTCTTAGATCTATAGAACGAGCTAACCCT
   AlaSerGlnAlaPheLysIleGluThrThrProGluSerArgTyrLeuAlaGlnIleGly -
121 GACTCCGCTCTCATTGACTTGCAGCACCAACAGGCTGTGAGTCCCCATTTTCTCTTGGAGA 180
   +-----+-----+-----+-----+-----+-----+
   CTGAGGCAGAGTAACCTGAACGTCGTGGTGTCCGACACTCAGGGGTAAAAAGAGAACCTCT
   AspSerValSerLeuThrCysSerThrThrGlyCysGluSerProPhePheSerTrpArg -
181 ACCCAGATAGATGCCACTGAATGGGAAGGTGACGAATGAGGGGACCACATCTACGCTG 240
   +-----+-----+-----+-----+-----+-----+
   TGGGTCTATCTATCAGGTGACTTACCCTTCCACTGCTTACTCCCCCTGGTGTAGATGCGAC
   ThrGlnIleAspSerProLeuAsnGlyLysValThrAsnGluGlyThrThrSerThrLeu -
241 ACAATGAATCCTGTGTAGTTTTGGGAACGAGCACTCTTACCCTGTGCACAGCAACTTGTGAA 300
   +-----+-----+-----+-----+-----+-----+
   TGTTACTTAGGACAATCAAAACCCCTTGCTCGTGAGAATGGACACGTCGTGTTGAACACTT
   ThrMetAsnProValSerPheGlyAsnGluHisSerTyrLeuCysThrAlaThrCysGlu -
301 TCTAGGAAATTGGAAAAAGGAATCCAGGTGGAGATCTACTCTTTTCCCTAAGGATCCAGAG 360
   +-----+-----+-----+-----+-----+-----+
   AGATCCCTTTAACCTTTTTCCTTAGGTCCACCTCTAGATGAGAAAAGGATTCCCTAGGTCTC
   SerArgLysLeuGluLysGlyIleGlnValGluIleTyrSerPheProLysAspProGlu -

```

Fig. 1a

2/14

```

361  ATTCATTGAGTGGCCCTCTGGAGGCTGGGAAGCCGATCACAGTCAAGTGTTCAGTTGCT 420
      +-----+-----+-----+-----+-----+-----+
      TAAGTAAACTCACCGGAGACCTCCGACCCTTCGGCTAGTGTCAAGTTCACAAGTCAACGA
      ileHisLeuSerGlyProLeuGluAlaGlyLysProIleThrValLysCysSerValAla -
421  GATGTATACCCATTGACAGGCTGGAGATAGACTTACTGAAAGGAGATCATCTCATGAAG 480
      +-----+-----+-----+-----+-----+-----+
      CTACATATGGGTAAACTGTCCGACCCTCTATCTGAATGACTTTCCTCTAGTAGAGTACTTC
      AspValTyrProPheAspArgLeuGluIleAspLeuLeuLysGlyAspHisLeuMetLys -
481  AGTCAGGAATTTCTGGAGGATGCCAGACAGGAAGTCCCTGGAAACCAAGAGTTTGGAAAGTA 540
      +-----+-----+-----+-----+-----+-----+
      TCAGTCCTTAAAGACCCTCCTACGTCTGTCTTCAGGGACCTTTGGTTCTCAAACCTTCAT
      SerGlnGluPheLeuGluAspAlaAspArgLysSerLeuGluThrLysSerLeuGluVal -
541  ACCTTTACTCCTGTCAATTGAGGATATTGGAAAAGTTCTTGTTCGCGAGCTAAATTACAC 600
      +-----+-----+-----+-----+-----+-----+
      TGGAAATGAGGACAGTAACTCCTATAACCTTTTCAAGAACAACGGCTCGATTTAATGTG
      ThrPheThrProValIleGluAspIleGlyLysValLeuValCysArgAlaLysLeuHis -
601  ATTGATGAAATGGATTCTGTGCCCCACAGTAAGGCAGGCTGTAAAAGAAATTGCAAGTCTAC 660
      +-----+-----+-----+-----+-----+-----+
      TAACTACTTTACCTAAGACACGGGTGTCAATCCGTCGCGACATTTTCTTAAACGTTTCAGATG
      ileAspGluMetAspSerValProThrValArgGlnAlaValLysGluLeuGlnValTyr -
661  ATATCACCCCAAGAATACAGTTATTTCTGTGAATCCATCCACAAAGCTGCAAGAAGGTGGC 720
      +-----+-----+-----+-----+-----+-----+
      TATAGTGGGTTCTTATGTCAATAAAGACACTTAGGTAGGTGTTTCGACGTTCTTCCACCCG
      ileSerProLysAsnThrValIleSerValAsnProSerThrLysLeuGlnGluGlyGly -

```

Fig. 1b



3/14

```

721 TCTGTGACCATGACCTGTTCCAGCGAGGGTCTACCAGCTCCAGAGATTTTCTGGAGTAAG
-----+-----+-----+-----+-----+-----+
780 AGACACTGGTACTGGACAAGGTCGCTCCAGATGGTCGAGGTCTCTAAAAGACCTCATTC
-----+-----+-----+-----+-----+-----+
SerValThrMetThrCysSerSerGluGlyLeuProAlaProGluIlePheTrpSerLys -
AAATTAGATAAATGGGAAATCTGCAGCACCTTTCTGGAAATGCAACTCTCACCTTAATTGCT
781 -----+-----+-----+-----+-----+-----+
840 TTTAATCTATTACCCTTAGACGTCGTCGGAAAGACCTTTACGTTGAGAGTGGAATTAAACGA
-----+-----+-----+-----+-----+-----+
LysLeuAspAsnGlyAsnLeuGlnHisLeuSerGlyAsnAlaThrLeuThrLeuIleAla -
ATGAGGATGGGAAGATTCTGGAATTATGTGTGTGAAGGAGTTAATTTGATTGGGAAAAAAC
841 -----+-----+-----+-----+-----+-----+
900 TACTCCTACCTTCTAAGACCTTAAATACACACACTTCCTCAATTAAACTAACCCCTTTTGG
-----+-----+-----+-----+-----+-----+
MetArgMetGluAspSerGlyIleTyrValCysGluGlyValAsnLeuIleGlyLysAsn -
AGAAAAGAGGTGGAATTAAATTGTTCAAGAGAAACCATTTACTGTTGAGATCTCCCCCTGGA
901 -----+-----+-----+-----+-----+-----+
960 TCTTTTCTCCACCTTAATTAACAAGTTCTCTTTGGTAAATGACAACTCTAGAGGGGACCT
-----+-----+-----+-----+-----+-----+
ArgLysGluValGluLeuIleValGlnGluLysProPheThrValGluIleSerProGly -
CCCCGGATTGCTGCTCAGATTGGAGACTCAGTCATGTTGACATGTAGTGTATGGGCTGT
961 -----+-----+-----+-----+-----+-----+
1020 GGGGCCTAACGACGAGTCTAACCTCTGAGTCAGTACAACTGTACATCACAGTACCCGACA
-----+-----+-----+-----+-----+-----+
ProArgIleAlaAlaGlnIleGlyAspSerValMetLeuThrCysSerValMetGlyCys -
GAATCCCCCATCTTTCTCCTGGAGAACCCAGATAGACAGCCCTCTGAAACGGGAAGGTGAGG
1021 -----+-----+-----+-----+-----+-----+
1080 CTTAGGGGTAGAAAGAGGACCTCTTGGGTCTATCTGTGCGGGAGACTTGCCCTTCCACTCC
-----+-----+-----+-----+-----+-----+
GluSerProSerPheSerTrpArgThrGlnIleAspSerProLeuAsnGlyLysValArg -

```

Fig. 1c

4/14

1081 AGTGAGGGACCAATTCCACGCTGACCCCTGAGCCCTGTGAGTTTGTAGAACGAACTCT  
 TCACTCCCTGGTTAAGGTGCGACTGGGACTCGGGACACTCAAACTCTTGTGCTGTGAGA  
 SerGluGlyThrAsnSerThrLeuThrLeuSerProValSerPheGluAsnGluHisSer -  
 1140  
 1141 TATCTGTGCACAGTGACTTGTGGACATAAGAACTGGAAAAAGGAATCCAGGTGGAGCTC  
 ATAGACACGTGTCACTGAACACCTGTATTCTTTGACCTTTTCCCTTAGGTCCACCTCGAG  
 TyrLeuCysThrValThrCysGlyHisLysLysLeuGluLysGlyIleGlnValGluLeu -  
 1200  
 1201 TACTCATTCCTAGAGATCCAGAAATCGAGATGAGTGGTGGCCCTCGTGAATGGGAGCTCT  
 ATGAGTAAGGATCTCTAGGTCTTTAGCTCTACTCACCCGAGCACTTACCCTCGAGA  
 TyrSerPheProArgAspProGluIleGluMetSerGlyGlyLeuValAsnGlySerSer -  
 1261 GTCACGTAAAGCTGCAAGGTTCTAGCGTGTACCCCTTGACCCGGCTGGAGATTGAATTA  
 CAGTGACATTTCGACGTTCCAAAGGATCGCACATGGGGGAACCTGGCCGACCTCTAACTTAAT  
 ValThrValSerCysLysValProSerValTyrProLeuAspArgLeuGluIleGluLeu -  
 1321 CTTAAGGGGGAGACTATTCTGGAGAAATATAGAGTTTTTGGAGGATACGGATATGAAATCT  
 GAATTCCTCCCTCTGATAAGACCTCTTATATCTCAAAACCTCCTATGCCTATACCTTTAGA  
 LeuLysGlyGluThrIleLeuGluAsnIleGluPheLeuGluAspThrAspMetLysSer -  
 1381 CTAGAGAACAAAAGTTTGAAATGACCTTCATCCCTACCATTGAAGATACTGGAAAAAGCT  
 GATCTCTTGTTTTCAAACTTTACTGGAAGTAGGATGGTAACCTTCTATGACCTTTTCGA  
 LeuGluAsnLysSerLeuGluMetThrPheIleProThrIleGluAspThrGlyLysAla -  
 1440

Fig. 1d

5/14

```

1441 CTTGTTTGT CAGGCTAAGTTACATATTGATGACATGGAAATTCGAACCCAAACAAAGGCAG
-----+-----+-----+-----+-----+-----+-----+
1500 GAACAAACAGTCCGATTCAATGTATATACTACTGTACCTTAAGCTTGGGTTTGTTCCTCGTC

LeuValCysGlnAlaLysLeuHisIleAspAspMetGluPheGluProLysGlnArgGln -

1501 AGTACGCAAAACACTTTATGTCAATGTTGCCCCAGAGATACAACCGTCTTGGTCAGCCCT
-----+-----+-----+-----+-----+-----+-----+
1560 TCATGCGTTTGTGAAATACAGTTACAACGGGGTCTCTATGTTGGCAGAACCAAGTCGGGA

SerThrGlnThrLeuTyrValAsnValAlaProArgAspThrThrValLeuValSerPro -

1561 TCCTCCATCCTGGAGGAGGCAGTTCTGTGAATATGACATGCTTGAGCCAGGGCTTTCCT
-----+-----+-----+-----+-----+-----+-----+
1620 AGGAGTAGGACCTCCTTCCGTCAAGACACTTATACTGTACGAACTCGGTCCCCGAAAGGA

SerSerIleLeuGluGluGlySerSerValAsnMetThrCysLeuSerGlnGlyPhePro -

1621 GTCCTCGAAAAATCCTGTGGAGCAGGCAGCTCCCTAACGGGGAGCTACAGCCTCTTCTGAG
-----+-----+-----+-----+-----+-----+-----+
1680 CGAGGCTTTTAGGACACCTCGTCCGTGAGGGATTGCCCCCTCGATGTCCGAGAAAGACTC

AlaProLysIleLeuTrpSerArgGlnLeuProAsnGlyGluLeuGlnProLeuSerGlu -

1681 AATGCAACTCTCACCTTAATTTCTACAAAAATGGAAGATTCTGGGGTTTATTTATGTGAA
-----+-----+-----+-----+-----+-----+-----+
1740 TTACGTTGAGAGTGGAATTAAGATGTTTTTACCTTCTAAGACCCCAATAAATACACTT

AsnAlaThrLeuThrLeuIleSerThrLysMetGluAspSerGlyValTyrLeuCysGlu -

1741 GGAATTAACCAAGGCTGGAAGAACAGAAAGGAAGTGAATTAATATATCCGAGTTACTCCA
-----+-----+-----+-----+-----+-----+-----+
1800 CCTTAATTGGTCCGACCTTCTTCGTCTTTCCTTCACTTAATTAATAGGCTCAATGAGGT

GlyIleAsnGlnAlaGlyArgSerArgLysGluValGluLeuIleIleArgValThrPro -

```

Fig. 1e

6/14

```

1801 AAAGACATAAACTTACAGCTTTTCCTTCTGAGAGTGTCAAAGAGGAGACACTGTTCATC 1860
      +-----+-----+-----+-----+-----+-----+
      TTTCTGTATTTTGAATGTCGAAAAGGAAGACTCTCACAGTTTCTTCTCTGTGACAGTAG

      LysAspIleLysLeuThrAlaPheProSerGluSerValLysGluGlyAspThrValIle -
1861 ATCTCTGTACATGTGGAATGTTCCAGAAACATGGATAATCCTGAAGAAAAAGCGGAG 1920
      +-----+-----+-----+-----+-----+-----+
      TAGAGAACATGTACACCTTTACAAGGCTTTGTACCTATTAGGACTTCTTTTTCGCCTC

      IleSerCysThrCysGlyAsnValProGluThrTrpIleIleLeuLysLysLysAlaGlu -
1921 ACAGGAGACACAGTACTAAAATCTATAGATGGCGCCTATACCATCCGAAAGCCCCAGTTG 1980
      +-----+-----+-----+-----+-----+-----+
      TGTCCCTCTGTGTCATGATTTTAGATATCTACCGCGGATATGGTAGGCTTCCGGGTCAAC

      ThrGlyAspThrValLeuLysSerIleAspGlyAlaTyrThrIleArgLysAlaGlnLeu -
1981 AAGGATCGGGAGTATATGAATGTGAATCTAAAAACAAGTTGGCTCACAAATTAAGAAGT 2040
      +-----+-----+-----+-----+-----+-----+
      TTCCTACGCCCTCATATACTTACACTTAGATTTTGTTCACCCGAGTGTTAATTCTTCA

      LysAspAlaGlyValTyrGluCysGluSerLysAsnLysValGlySerGlnLeuArgSer -
2041 TTAACACTTGATGTTCAAGGAAGAGAAAAACAACAAGACTATTTTCTCTGAGCTTCTC 2100
      +-----+-----+-----+-----+-----+-----+
      AATTGTGAAC TACAAGTTCCTTCTCTTTTGTGTTCTCTGATAAAAAGAGGACTCGAAGAG

      LeuThrLeuAspValGlnGlyArgGluAsnAsnLysAspTyrPheSerProGluLeuLeu -
2101 GTGCTCTATTTTGCATCCCTCCTTAATAATACCTGCCATTGGAAATGATAATTTACTTTGCA 2160
      +-----+-----+-----+-----+-----+-----+
      CACGAGATAAAACGTAGGAGGAATTATTATGGACGGTAACCTTACTATTAAATGAAACGT

      ValLeuTyrPheAlaSerSerLeuIleIleProAlaIleGlyMetIleIleTyrPheAla -

```

Fig. 1f

7/14

2161 AGAAAGCCCAACATGAAGGGGTCATATAGTCTTGTAAGCACACAGAAATCAAAAGTGTAG + 2220  
-----+-----+-----+-----+-----+-----+-----+-----+  
TCCTTTCGGTGTACTTCCCCAGTATATCAGAACATCTTCGTGCTCTTAGTTTTCACATC  
ArgLysAlaAsnMetLysGlySerTyrSerLeuValGluAlaGlnLysSerLysValEnd -

Fig. 1g

8/14

```

1 .....EKPFTVEISPGPRIAAQIGDSVMLTCSVM 29
      | | | | | | | | | |
1 MPGKMVVILGASNILWIMFAASQAFKIETTPESRYLAQIGDSVSLTCSTT 50
      . . . . .
30 GCESPSFSWRTQIDSPLNGKVRSEGTNSTLTLSPVSFENEHSYLCTVTCG 79
      | | | | | | | | | | | | | | | | | | | | | | | | | |
51 GCESPFFSWRTQIDSPLNGKVTNEGTTSTLTMPVSVFGNEHSYLCTATCE 100
      . . . . .
80 HKKLEKGIQVELYS..... 93
      | | | | | | | | | |
101 SRKLEKGIQVEIYSFPKDPEIHLSGPLEAGKPITVKCSVADVYPFDRLEI 150

```

Fig. 2

9/14

```

1  ATGCTGGGAAGATGGTCGTGATCCCTTGGAGCCCTCAAATATACCTTTGGATAATGTTTGCA 60
   TACGGACCCCTTCTACCCAGCACTAGGAACCTCGGAGTTTATATGAAACCTATTACAAACGT
MetProGlyLysMetValIleLeuGlyAlaSerAsnIleLeuTrpIleMetPheAla -
61  GCTTCTCAAGCTTTTAAATCGAGACCAACCCAGAAATCTAGATATCTTGCTCAGATTGGT 120
   CGAAGAGTTCGAAAATTTTAGCTCTGGTGGGTCTTAGATCTATAGAACGAGTCTAACCA
AlaSerGlnAlaPheLysIleGluThrThrProGluSerArgTyrLeuAlaGlnIleGly -
121 GACTCCGCTCTCATTGACTTGCAGACCAACAGGCTGTGAGTCCCCCATTTTCTCTTGGAGA 180
   CTGAGGCAGAGTAACGTCGTGGTGTCCGACACTCAGGGGTAAAAAGAGAACCTCT
AspSerValSerLeuThrCysSerThrThrGlyCysGluSerProPhePheSerTrpArg -
181 ACCCAGATAGATAGTCCACTGAATGGGAAGGTGACGAATGAGGGGACCACATCTACGCTG 240
   TGGGTCTATCTATCAGGTGACTTACCCTTCCACTGCTTACTCCCTGGTGTAGATGCGAC
ThrGlnIleAspSerProLeuAsnGlyLysValThrAsnGluGlyThrThrSerThrLeu -
241 ACAATGAATCCTGTAGTTTTTGGAAACGAGCACTCTTACCTGTGCACAGCAACTTGTGAA 300
   TGTTACTTAGGACAAATCAAAACCCCTTGCTCGTGAGAAATGGACACGTCGTTGAACACTT
ThrMetAsnProValSerPheGlyAsnGluHisSerTyrLeuCysThrAlaThrCysGlu -
301 TCTAGGAAAATTGGAAAAAGGAATCCAGGTGGAGATCTACTCTTTTCTAAGGATCCAGAG 360
   AGATCCTTTAACCTTTTTCCTTAGGTCCACCTCTAGATGAGAAAAGGATTCCTAGGTCTC
SerArgLysLeuGluLysGlyIleGlnValGluIleTyrSerPheProLysAspProGlu -

```

Fig. 3a

10/14

```

361  ATTCAATTGAGTGGCCCTCTGGAGGCTGGGAAGCCGATCACAGTCAAGTGTTCAGTTGCT
      +-----+-----+-----+-----+-----+
420  TAAGTAAACTCACCGGAGACCTCCGACCCCTTCGGCTAGTGTTCAGTTCAAAAGTCAACGA
      +-----+-----+-----+-----+-----+
      IleHisLeuSerGlyProLeuGluAlaGlyLysProIleThrValLysCysSerValAla -

421  GATGTATACCCATTGTACAGGCTGGAGATAGACTTACTGAAAGGAGATCATCTCATGAAG
      +-----+-----+-----+-----+-----+
480  CTACATATGGGTAAACTGTCCGACCTCTATCTGAATGACTTTCCTCTAGTAGACTTCTC
      +-----+-----+-----+-----+-----+
      AspValTyrProPheAspArgLeuGluIleAspLeuLeuLysGlyAspHisLeuMetLys -

481  AGTCAGGAATTTCTGGAGGATGCAGACAGGAAGTCCCTGGAAACCAAGAGTTTGGAAAGTA
      +-----+-----+-----+-----+-----+
540  TCAGTCCTTAAAGACCTCCTACGCTGTCTCCTTCAGGGACCTTTGGTTCTCAAAACCTTCAT
      +-----+-----+-----+-----+-----+
      SerGlnGluPheLeuGluAspAlaAspArgLysSerLeuGluThrLysSerLeuGluVal -

541  ACCTTTACTCCTGTCATTGAGGATATTGGAAAAGTTCTTGTGTTGCCGAGCTAAATTACAC
      +-----+-----+-----+-----+-----+
600  TGGAAATGAGGACAGTAACCTCCTATAACCTTTTCAAGAACAACCGGCTCGATTAAATGTG
      +-----+-----+-----+-----+-----+
      ThrPheThrProValIleGluAspIleGlyLysValLeuValCysArgAlaLysLeuHis -

601  ATTGATGAAATGGATTCTGTGCCCCACAGTAAGGCAGGCTGTAAAAGAAATTGCAAGTCTAC
      +-----+-----+-----+-----+-----+
660  TAACTACTTTACCTAAGACACGGGTGTCATTCCGTCGACATTTTCTTAACGTTTCAGATG
      +-----+-----+-----+-----+-----+
      IleAspGluMetAspSerValProThrValArgGlnAlaValLysGluLeuGlnValTyr -

661  ATATCACCCCAAGAAATACAGTTATTTCTGTGAATCCCATCCACAAGCTGCAAGAAAGGTGGC
      +-----+-----+-----+-----+-----+
720  TATAGTGGGTTCTTATGTCAATAAAGACACTTAGGTAGGTGTTTCGACGTTCTTCCACCCG
      +-----+-----+-----+-----+-----+
      IleSerProLysAsnThrValIleSerValAsnProSerThrLysLeuGlnGluGlyGly -

```

Fig. 3b



11/14

TCTGTGACCATGACCTGTTCACGCGAGGGTCTACCAGCTCCAGAGATTTTCTGGAGTAAG 721  
 -----+-----+-----+-----+-----+-----+-----+  
 AGACACTGGTACTGGACAAGTCCGCTCCAGATGGTCGAGGTCTCTAAAAGACCTCATTC 780  
 -----+-----+-----+-----+-----+-----+-----+  
 SerValThrMetThrCysSerSerGluGlyLeuProAlaPheTrpSerLys -  
 AAATTAGATAATGGGAATCTGCAGCACCTTTCTGGAAATGCCAACTCTCACCTTAATTGCT 841  
 -----+-----+-----+-----+-----+-----+-----+  
 TTTAATCTATTACCCTTAGACGTCGTGGAAAGACCTTTACGTTGAGAGTGGAAATTAACGA 840  
 -----+-----+-----+-----+-----+-----+-----+  
 LysLeuAspAsnGlyAsnLeuGlnHisLeuSerGlyAsnAlaThrLeuThrLeuIleAla -  
 ATGAGGATGGAAGATTCTGGAATTTATGTGTGTGAAGGAGTTAATTTGATTGGGAAAAAC 901  
 -----+-----+-----+-----+-----+-----+-----+  
 TACTCCTACCTTCTAAGACCTTAAATACACACACTTCCTCAATTAAACTAACCCCTTTTGG 900  
 -----+-----+-----+-----+-----+-----+-----+  
 MetArgMetGluAspSerGlyIleTyrValCysGluGlyValAsnLeuIleGlyLysAsn -  
 AGAAAAGAGGTGGAATTAATTGTTCAAGAGAAACCATTACTGTTGAGATCTCCCCCTGGA 961  
 -----+-----+-----+-----+-----+-----+-----+  
 TCTTTTCTCCACCTTAATTAACAAGTCTCTTTGGTAAATGACAACTCTAGAGGGGACCT 960  
 -----+-----+-----+-----+-----+-----+-----+  
 ArgLysGluValGluLeuIleValGlnGluLysProPheThrValGluIleSerProGly -  
 CCCC GGATTGCTGCTCAGATTGGAGACTCAGTCATGTTGACATCTAGTGTCTATGGGCTGT 1021  
 -----+-----+-----+-----+-----+-----+-----+  
 GGGCCCTAACGACGAGTCTAACCTCTGAGTCAGTACAACTGTACATCACAGTACCCGACA 1020  
 -----+-----+-----+-----+-----+-----+-----+  
 ProArgIleAlaAlaGlnIleGlyAspSerValMetLeuThrCysSerValMetGlyCys -  
 GAATCCCCCATCTTTCTCCTGGAGAACCCAGATAGACAGCCCCCTCTGAACGGGAAGGTGAGG 1081  
 -----+-----+-----+-----+-----+-----+-----+  
 CTTAGGGGTAGAAAGAGGACCTCTTGGGTCTATCTGTCTGGGAGACTTGCCCTTCCACTCC 1080  
 -----+-----+-----+-----+-----+-----+-----+  
 GluSerProSerPheSerTrpArgThrGlnIleAspSerProLeuAsnGlyLysValArg -

Fig. 3c

12/14

1081 AGTGAGGGGACCAATTCCACGCTGACCCCTGAGCCCTGTGAGTTTGTGAGAACGAACACTCT  
 -----+-----+-----+-----+-----+-----+-----+  
 TCACTCCCTGGTTAAGGTGGAGCTGGGACTCGGACACTCAAAACTCTTGCTTGTGAGA 1140  
 SerGluGlyThrAsnSerThrLeuThrLeuSerProValSerPheGluAsnGluHisSer  
 1141 TATCTGTGCACAGTGACTTGTGGACATAAGAAACTGGAAAAGGGAATCCAGGTGGAGCTC  
 -----+-----+-----+-----+-----+-----+-----+  
 ATAGACACGTTGTCACCTGAACACCTGTATTCTTTGACCTTTTCCCTTAGGTCCACCTCGAG 1200  
 TyrLeuCysThrValThrCysGlyHisLysLysLeuGluLysGlyIleGlnValGluLeu -  
 1201 TACTCATTCCTTAGAGATCCAGAAATCGAGATGAGTGGTGGCCCTCGTGAATGGGAGCTCT  
 -----+-----+-----+-----+-----+-----+-----+  
 ATGAGTAAGGGATCTCTAGGTCTTTAGCTCTACTCACCACCGGAGCACTTACCCTCGAGA 1260  
 TyrSerPheProArgAspProGluIleGluMetSerGlyGlyLeuValAsnGlySerSer -  
 1261 GTCACGTGAAGCTGCAAGGTTCTTAGCGGTGTACCCCTTGACCCGGCTGGAGATTGAATTA  
 -----+-----+-----+-----+-----+-----+-----+  
 CAGTGACATTTCGACGTTCCAAGGATCGCACATGGGGAACTGGCCGACCTCTAACTTAAT 1320  
 ValThrValSerCysLysValProSerValTyrProLeuAspArgLeuGluIleGluLeu -  
 1321 CTTAAGGGGAGAGACTATTCTGGAGAATATAGAGTTTGTGGAGGATACGGATATGAAATCT  
 -----+-----+-----+-----+-----+-----+-----+  
 GAATTCCCTCTGTATAAGACCTCTTATATCTCAAAAACCTCCTATGCCTATACCTTTAGA 1380  
 LeuLysGlyGluThrIleLeuGluAsnIleGluPheLeuGluAspThrAspMetLysSer -  
 1381 CTAGAGAACAAAAGTTTGGAAATGACCTTCATCCCTACCATTGAAGATACTGGAAAAGCT  
 -----+-----+-----+-----+-----+-----+-----+  
 GATCTCTGTTTTCAAAACCTTTACTGGAAGTAGGGATGGTAACTTCTATGACCTTTTCGA 1440  
 LeuGluAsnLysSerLeuGluMetThrPheIleProThrIleGluAspThrGlyLysAla -

Fig. 3d

13/14

1441 CTTGTTTGTTCAGGCTAAGTTACATATATGATGACATGGAATTCGAACCCAAACAAAGGCAG  
 -----+-----+-----+-----+-----+-----+-----+  
 GAAACAACAGTCCGATTCAATGTATAACTACTGTACCTTAAGCTTGGGTTTGGTTTCCGTC  
 LeuValCysGlnAlaLysLeuHisIleAspAspMetGluPheGluProLysGlnArgGln -  
 1501 AGTACGCAAAACACTTTATGTCAATGTTGCCCCAGAGATACAACCGTCTTGGTCAGCCCT  
 -----+-----+-----+-----+-----+-----+-----+  
 TCATGCGTTTGTGAAATACAGTTACAACGGGGTCTCTATGTTGGCAGAACCCAGTCGGGA  
 SerThrGlnThrLeuTyrValAsnValAlaProArgAspThrThrValLeuValSerPro -  
 1561 TCCTCCATCCTGGAGGAAGCAGTTCTGTGAATATGACATGCTTGAGCCAGGGCTTTCCT  
 -----+-----+-----+-----+-----+-----+-----+  
 AGAGGTAGGACCTCCTTCCGTCAAGACACTTACTGTACGAACTCGGTCCCGAAAGGA  
 SerSerIleLeuGluGluGlySerSerValAsnMetThrCysLeuSerGlnGlyPhePro -  
 1621 GCTCCGAAAATCCTGTGGAGCAGGAGCTCCCTAACGGGGAGCTACAGCCCTCTTCTGAG  
 -----+-----+-----+-----+-----+-----+-----+  
 CGAGGCTTTTAGGACACCTCGTCCGTCGAGGGATTGCCCTCGATGTCGGAGAAAGACTC  
 AlaProLysIleLeuTrpSerArgGlnLeuProAsnGlyGluLeuGlnProLeuSerGlu -  
 1681 AATGCAACTCTCACCTTAATTTCTACAAAAATGGAAGATTCTGGGGTTTATTTATGTGAA  
 -----+-----+-----+-----+-----+-----+-----+  
 TTACGTTGAGAGTGGAAATTAAGATGTTTTTACCTTCTAAGACCCCAATAAATACACTT  
 AsnAlaThrLeuThrLeuIleSerThrLysMetGluAspSerGlyValTyrLeuCysGlu -  
 1741 GGAATTAAACCAGGCTGGAAGAAGCAGAAAGGAAGTGAATTAATTATCCGAGTTACTCCA  
 -----+-----+-----+-----+-----+-----+-----+  
 CCTTAATTGGTCCGACCTTCTTCGTCTTTCTCCTTACCTTAATTAATAGGCTCAATGAGGT  
 GlyIleAsnGlnAlaGlyArgSerArgLysGluValGluLeuIleIleArgValThrPro -  
 1800

Fig. 3e

14/14

```

1801 AAAGACATAAACTTACAGCTTTTCCTTCTGAGAGTGTCAAAGAAAGGAGACACTGTTCATC
      +-----+-----+-----+-----+-----+-----+
      TTTCTGTATTTTGAATGTCGAAAAGGAAGACTCTCACAGTTTCTTCCTCTGTGACAGTAG
      +-----+-----+-----+-----+-----+-----+ 1860
      LysAspIleLysLeuThrAlaPheProSerGluSerValLysGluGlyAspThrValIle -
      ATCTCTTGACATGTGGAAAATGTTCCAGAAACATGGATAATCCTGAAGAAAAAGCGGAG
      +-----+-----+-----+-----+-----+-----+
      TAGAGAACATGTACACCTTTACAAGGTCTTTGTACCTATTAGGACTTCTTTTTCGCCCTC
      +-----+-----+-----+-----+-----+-----+ 1920
      IleSerCysThrCysGlyAsnValProGluThrTrpIleIleLeuLysLysAlaGlu-
      ACAGGAGACACAGTACTAAATCTATAGATGGCGCCTATACCATCCGAAAGGCCAGTTG
      +-----+-----+-----+-----+-----+-----+
      TGTCTCTGTGTCATGATTTTAGATATCTACCGCGGATATGGTAGGCTTCCGGGTCAAC
      +-----+-----+-----+-----+-----+-----+ 1980
      ThrGlyAspThrValLeuLysSerIleAspGlyAlaTyrThrIleArgLysAlaGlnLeu -
      AAGGATCGGGGAGTATATGAATGTGAATCTAAAAACAAAGTTGGCTCACAAATTAAGAA
      +-----+-----+-----+-----+-----+-----+
      TTCCTACGCCCTCATATACTTACACTTAGATTTTGTTCACCCGAGTGTAAATTTCTCA
      +-----+-----+-----+-----+-----+-----+ 2040
      LysAspAlaGlyValTyrGluCysGluSerLysAsnLysValGlySerGlnLeuArgSer -
      TTAACTTGTGATGTTCAAGGAAGAGAAAAACAACAAGACTATTTTCTTAG
      +-----+-----+-----+-----+-----+-----+
      AATTGTGAACACTACAAGTTCCTTCTCTTTTGTGTTCTGTGATAAAAAGAATC
      +-----+-----+-----+-----+-----+-----+ 2091
      LeuThrLeuAspValGlnGlyArgGluAsnAsnLysAspTyrPheSerEnd -

```

Fig. 3f

# INTERNATIONAL SEARCH REPORT

International Application No PCT/DK 91/00193

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC <b>IPC5: A 61 K 37/02</b>						
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; margin-top: 5px;">Minimum Documentation Searched<sup>7</sup></div> <table style="width: 100%; border: none;"> <tr> <td style="width: 25%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">Classification System</div> </td> <td style="border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">Classification Symbols</div> </td> </tr> <tr> <td style="border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">IPC5</div> </td> <td style="border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">A 61 K; G 01 N; C 12 Q; C 12 N</div> </td> </tr> </table> <div style="text-align: center; margin-top: 5px; font-size: small;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched<sup>8</sup></div>			<div style="border: 1px solid black; padding: 2px;">Classification System</div>	<div style="border: 1px solid black; padding: 2px;">Classification Symbols</div>	<div style="border: 1px solid black; padding: 2px;">IPC5</div>	<div style="border: 1px solid black; padding: 2px;">A 61 K; G 01 N; C 12 Q; C 12 N</div>
<div style="border: 1px solid black; padding: 2px;">Classification System</div>	<div style="border: 1px solid black; padding: 2px;">Classification Symbols</div>					
<div style="border: 1px solid black; padding: 2px;">IPC5</div>	<div style="border: 1px solid black; padding: 2px;">A 61 K; G 01 N; C 12 Q; C 12 N</div>					
SE,DK,FI,NO classes as above						
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>						
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>				
Y	EP, A2, 0314863 (BAYLOR COLLEGE OF MEDICINE ET AL.) 10 May 1989, see esp. the claims <div style="text-align: center; margin-top: 20px;">--</div>	1-2,7-9, 12-14, 18-19, 20-22, 25,27- 28				
Y	WO, A1, 9003400 (DANA-FARBER CANCER INSTITUTE) 5 April 1990, see esp. the claims <div style="text-align: center; margin-top: 20px;">--</div>	1-2,7-9, 12-14, 18-19, 20-22, 25,27- 28				
Y	Dialog Information Services, File 154, Medline 85-91 Dialog accession no. 07243285, Elices M.J. et al: "VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site", & Cell Feb 23 1990, 60 (4) p577-84 <div style="text-align: center; margin-top: 20px;">--</div>	1-2,7-9, 12-14, 18-19, 20-22, 25,27- 28				
<div style="display: flex; justify-content: space-between; font-size: x-small;"> <div style="width: 45%;"> <p>* Special categories of cited documents:<sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>						
<b>IV. CERTIFICATION</b>						
Date of the Actual Completion of the International Search  <b>17th December 1991</b>	Date of Mailing of this International Search Report  <div style="text-align: center; font-size: large;">1991 -12- 18</div>					
International Searching Authority  <div style="text-align: center; font-weight: bold;">SWEDISH PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; font-family: cursive;">Carolina Palmcrantz</div> <div style="text-align: center; font-weight: bold;">Carolina Palmcrantz</div>					

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	EP, A2, 0333517 (THE ROCKEFELLER UNIVERSITY) 20 September 1989, see esp. the abstract --	1-2,7-8
P,X	WO, A1, 9013300 (BIOGEN, INC.) 15 November 1990, see the whole document --	1-2,9, 12,20- 22,25
T	J. Clin. Invest., Vol. 88, July 1991 A: Dobrina et al.: "Mechanisms of Eosinophil Adherence to Cultured Vascular Endothelial Cells", see page 20 - page 26 -- -----	1-2

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 18-19 because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☒ Claim numbers 2, 4-6, 21 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

and other claims as far as they include the too broadly formulated wordings "variant", "a derivative thereof", "is fused to another Ig superfamily molecule", "a fragment thereof".

3. ☐ Claim numbers..... because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

See the attached sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim number.
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED**

The subjects, as listed below, are so different from each other that no technical relationship can be appreciated to be present so as to form a single general inventive concept.

Invention A (claims 1-8, 20-24) describes a pharmaceutical composition comprising a vascular cell adhesion molecule (VCAM).

Further, invention B (claims 9-12, 25-27 and partly 29) describes a pharmaceutical composition comprising an antibody which is capable of binding a VCAM.

Invention C (claims 13-17, 28 and partly 29) describes a method of screening for antagonists of VCAM binding to eosinophils.



ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. PCT/DK 91/00193

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on 31/10/91. The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0314863	89-05-10	AU-D- 1550988	89-07-27
		AU-D- 2633388	89-07-27
		JP-A- 1135724	89-05-29
WO-A1- 9003400	90-04-05	AU-D- 4412889	90-04-18
		EP-A- 0365837	90-05-02
		JP-T- 3501861	91-04-25
		AU-D- 5129990	90-09-20
		JP-A- 3157397	91-07-05
EP-A2- 0333517	89-09-20	AU-D- 3149289	89-09-21
		JP-A- 2076898	90-03-16
WO-A1- 9013300	90-11-15	AU-D- 6049290	90-11-29